← Back to Search

Atomic Magnetometer Brain Imaging for Epilepsy

N/A
Recruiting
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
BOTH projects: are unable to offer independent informed consent to study participation.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day (during the brain scan)
Awards & highlights
No Placebo-Only Group

Summary

This trial will help researchers learn if an atomic magnetometer can be used for brain imaging, and if it is as effective as the current method which uses a SQUID-based cryogenic sensor.

Who is the study for?
This trial is for adults aged 18-70 with epilepsy, referred through the clinical MEG program. It's not for pregnant women, those unable to consent, people with neurological disorders other than epilepsy or who can't lie still during recording, and anyone with metal implants that could interfere with sensor readings.
What is being tested?
The study tests a new brain imaging device using OPM sensors against the traditional SQUID sensors in Magnetoencephalography (MEG). The goal is to see if OPMs offer a non-invasive way to monitor brain activity at room temperature effectively.
What are the potential side effects?
Since this trial involves non-invasive imaging techniques rather than medication or surgery, side effects are minimal. However, discomfort from lying still and potential anxiety about being in an enclosed space during scanning may occur.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot give informed consent on my own.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day (during the brain scan)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day (during the brain scan) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Evoked and Induced MEG with OPM and SQUID sensors in healthy controls
Spontaneous MEG with OPM and SQUID sensors in patients with epilepsy

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: healthy adultsExperimental Treatment2 Interventions
Any adult, who is at least eighteen (18-70) years old.
Group II: Patients with intractable epilepsyExperimental Treatment2 Interventions
Any clinical patient referred to us via the clinical MEG program, and who is at least eighteen (18-70) years old.

Find a Location

Who is running the clinical trial?

University of Colorado, BoulderOTHER
124 Previous Clinical Trials
29,482 Total Patients Enrolled
University of Colorado, DenverLead Sponsor
1,806 Previous Clinical Trials
2,822,837 Total Patients Enrolled
6 Trials studying Epilepsy
1,202 Patients Enrolled for Epilepsy

Media Library

OPM sensors Clinical Trial Eligibility Overview. Trial Name: NCT04515316 — N/A
Epilepsy Research Study Groups: Patients with intractable epilepsy, healthy adults
Epilepsy Clinical Trial 2023: OPM sensors Highlights & Side Effects. Trial Name: NCT04515316 — N/A
OPM sensors 2023 Treatment Timeline for Medical Study. Trial Name: NCT04515316 — N/A
~1 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top